Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selegiline Transdermal System in Elderly Major Depression
NCT00285766Phase 3Completed
- Sponsor
- Somerset Pharma
- Start
- Aug 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of selegiline in major depressive disorder (MDD), sponsored by Somerset Pharma. Primary endpoint: Safety and Tolerability at 16 weeks. Started Aug 2002; status: completed.
02
Drugs
selegiline
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00285766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00285766.